Which thyroid-stimulating hormone level should be sought in hypothyroid patients under l-thyroxine replacement therapy?

2006 ◽  
Vol 60 (6) ◽  
pp. 655-659 ◽  
Author(s):  
A. Gursoy ◽  
M. Ozduman Cin ◽  
N. Kamel ◽  
S. Gullu
Author(s):  
T Wheatley ◽  
P M S Clark ◽  
J D A Clark ◽  
P R Raggatt ◽  
O M Edwards

Serum thyroid stimulating hormone (TSH) was measured using a highly sensitive enzyme-amplified immunoassay in 37 clinically euthyroid patients receiving thyroxine replacement therapy and compared with other biochemical tests of thyroid function. A highly significant correlation ( P<0·001) was found between the basal serum TSH and the increase in serum TSH concentration 20 min after the administration of thyrotropin releasing hormone (TRH). The basal serum TSH was negatively correlated with the serum total thyroxine ( P=0·05). When patients results were classified as abnormal or normal many discrepancies were noted between the various thyroid tests. A suppressed serum TSH was found in 65% of patients with a normal serum total thyroxine. However, in patients on thyroxine replacement therapy a basal TSH measured by enzyme-amplified immunoassay provides the same information as a TRH test.


2019 ◽  
Vol 31 (2) ◽  
pp. 45-49
Author(s):  
Asish Kumar Debnath ◽  
Md Azizul Haque ◽  
Partho Moni Bhattachyaria ◽  
Quazi Tarikul Islam ◽  
ARM Saifuddin Ekram

This study was carried out in the Department of Medicine, Rajshahi Medical College, in 2006-2007 to study the thyroid peroxidase (TPO) antibody level among hypothyroid patients and to find out the effects of L-thyroxine therapy in TPO-antibody titer. After thorough physical examination and relevant investigations, 100 patients of hypothyroidism were enrolled in this study. The selected patients were given L-thyroxine replacement therapy at a dose of 50-150 microgram/d. Before starting L-thyroxine, serum was collected from all patients to estimate anti TPO-antibody level. All patients were followed-up after 12-28 weeks of full dose of L-thyroxine therapy. Patients with high TPO-Abs at baseline, only 17.6% turned into euthyroid (based on composite clinical score), whereas about 42% of the patients who did not have high TPO-Abs became euthyroid suggesting that patients with high TPO Abs may show significantly poor response to treatment compared to the patients without high TPO Abs (p < 0.001). Patients with high TPO-Ab titers also showed a decreased biochemical response (TSH values) compared to the patients without high TPO-Ab positive patients. So, TPO-Ab plays a significant role in causation of the disease and is also associated with poor treatment response with L-thyroxine replacement therapy. TAJ 2018; 31(2): 45-49


1986 ◽  
Vol 113 (1) ◽  
pp. 47-49 ◽  
Author(s):  
Anders Wennlund

Abstract. Serum levels of T3, T4, FT4 and TSH were determined in 9 euthyroid patients during 6 h after intake of morning thyroxine replacement medication. Four hypothyroid patients were studied in the same way after the intake of 50 μg thyroxine. In the euthyroid patients the FT4 level increased by 31%, while the increase of T4 was 16% and the increase of T3 11%. In the hypothyroid patients levels of T3, T4 and FT4 did not change after ingestion of 50 μg thyroxine, while the TSH level was decreased by 30%. It is concluded that during thyroxine replacement therapy hormone analysis must be interpreted in relation to the time of thyroxine administration.


2015 ◽  
Vol 4 (3) ◽  
pp. 199 ◽  
Author(s):  
V Suresh ◽  
D Rajitha ◽  
E Sunil ◽  
M Arun ◽  
C Srinivasarao ◽  
...  

2020 ◽  
pp. 1-4
Author(s):  
Lauren Buehler ◽  
Alireza Movahed ◽  
Keren Zhou ◽  
M. Cecilia Lansang

Sign in / Sign up

Export Citation Format

Share Document